Report

FDA programs on the horizon: What biopharma companies need to know

Discover the U.S. FDA’s groundbreaking Commissioner’s National Priority Voucher (CNPV) program, a new initiative designed to accelerate drug review timelines to as little as 1–2 months for eligible biopharmaceuticals. 
With a focus on addressing public health crises, advancing innovative cures, and strengthening U.S. supply chain resiliency, the CNPV program offers a unique opportunity for biopharma companies to bring life-saving treatments to market faster.

The program reflects the FDA’s commitment to balancing innovation, affordability, and regulatory rigor while navigating the evolving healthcare landscape. Learn how your organization can adapt to this new regulatory paradigm, evaluate risks and opportunities, and prepare for success in an agile and fast-paced environment.

Download the report to learn more!
PDF preview
Pardot Form

Connect with our team

Our commitment to helping clients achieve market access plays a crucial role in patients’ access to affordable, diverse, and effective therapies so they can achieve their best potential health outcomes. Connect with our team of experts to discover how we can help support your goals.

Related resources

'"

Guide

Five strategic shifts to lead pharma through change
Learn more
HTA Quarterly

Article

HTA Quarterly Fall 2025 Summary
Learn more
HTAQ Summer 2025

Article

Changing evidence requirements for France’s Early Access Program (EAP): What could we see in the coming year?
Learn more

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.